Article Per Year (5 Year)
p-Index From 2021 - 2026
1.037
P-Index
This Author published in this journals
All Journal The Indonesian Biomedical Journal Nusantara Medical Science Journal Jurnal Respirologi Indonesia Respiratory Science Advance Sustainable Science, Engineering and Technology (ASSET)
Harun Iskandar
Hasanuddin University
Biochemistry, Genetics & Molecular Biology Chemistry Computer Science & IT Control & Systems Engineering Electrical & Electronics Engineering Health Professions Industrial & Manufacturing Engineering Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Public Health

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
The survival rate comparison of non small cell lung carcinoma patients who are given by epidermal growth factor receptor-tyrosin kinase inhibitor and those given by first-line chemotherapy treatment Hasan Nyambe; Arif Santoso; Nur Ahmad Tabri; Harun Iskandar; Muh Ilyas; Edward Pandu Wiriyansyah
Nusantara Medical Science Journal Volume 6 Issue 2, July - December 2021
Publisher : Faculty of Medicine, Hasanuddin University.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20956/nmsj.v6i2.18857

Abstract

Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Wahidin Sudirohusodo hospital. Methods. This study is a retrospective study between 2017 to 2019 from the medical records of NSCLC patients who receive first-line chemotherapy and thise who recieve EGFR-TKI. Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day and or afatinib 1x40 mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the  study is     discontinued. Result. From 239 subject of NSCLC patients consisted of 135 patients who receive first-line chemotherapy, and 104 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are more than 40 years old (chemotherapy 124 (91.9%) and EGFR-TKI 101 (97.1%) with the male gender that dominates (chemotherapy 98 (72.6%), EGFR-TKI 64 (61.5%). Smoking patients who received first-line chemotherapy are 65.2% and 61.5% of EGFR-TKIs with chemotherapy highest IB (severe IB 28.9%) and for EGFR-TKI (moderate IB are 26.9%). 73.2% of adenocarcinoma histology type with a predominance of stage IV 86.6% (83.7% for chemotherapy and EGFR-TKI 90.4%). Survival rate of patients are 98,7% for 6 months survival, 1 year survival rate is 94.1% and 2 years survival rate of 24.3%. Median survival patients who receiving EGFR-TKI longer than they received first- line chemotherapy (21 months versus 20 months). The 18 months PFS showed that patients treated with EGFR-TKI were 15 months, while patients receiving chemotherapy was 11 months. (P 0.000). Conclusion. Survival rates in NSCLC patients with EGFR-TKI therapy had significantly the highest survival rates compared with all other chemotherapy. Progression was faster in patients with first-line chemotherapy than EGFR-TKI. The factors that most influence the survival rate is type of therapy with p value<0.05.
Analysis of Vitamin D Levels on Bronchiectasis Severity Yacob Arawamin Batkunde; Muhammad Ilyas; Irawaty Djaharuddin; Nur Ahmad Tabri; Harun Iskandar; Arif Santoso
Respiratory Science Vol. 1 No. 2 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i2.11

Abstract

Background: Bronchiectasis is a chronic disease caused by repeated infection and inflammation of the bronchial walls. Vitamin D plays a role secretion of antimicrobial peptide and inhibits release of pro-inflammatory cytokines in the lungs. Vitamin D deficiency is associated with exacerbations, severity and decreased lung function in bronchiectasis. Several studies have found an association between vitamin D levels and bronchiectasis severity. Methods: This study used cross-sectional study design with consecutive sampling method on bronchiectasis patients who enrolled outpatient and inpatient at Wahidin Sudirohusodo hospital in February - May 2020. All research procedures obtained the approval of the Health Research Ethics Commission, Medicine faculty, Hasanuddin University Makassar. Bronchiectasis severity was assessed based on the FACED score (FEV1, Aged, chronic Colonization by Pseudomonas aeuroginosa, radiological Extension of the disease, Dyspnea). Levels of vitamin D serum {25 (OH) D} were checked using the ELISA method. Results: The study subjects were 44 patients, consisting of 61.4% male and 38.6% female. Most of the bronchiectasis patients in this study were mild (77.3%) based on the FACED score, 15.9% moderate and 6.8% severe. As many as 77.3% of patients had vitamin D deficiency and insufficiency as much as 9.1%. All patients with moderate-severe FACED scores had vitamin D deficiency. The correlation between vitamin D levels and FACED scores showed a positive significant with p-value 0.04. Conclusion: Low vitamin D levels are a risk factor for aggravating bronchiectasis severity and have a positive significant correlation between the two.
Surfactant Protein A Serum Level in Cement Worker Gunawan Gunawan; Sita Laksmi Andarini; Muhammad Ilyas; Arif Santoso; Ahmad Hudoyo; Irawaty Djaharudin; Harun Iskandar; Nur Ahmad Tabri
Jurnal Respirologi Indonesia Vol 42, No 4 (2022)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v42i4.363

Abstract

Background: Pneumoconiosis occurs almost in entire worldwide. Pneumoconiosis had threatened cement workers. Serologic abnormalities had found in pneumoconiosis. Surfactant Protein A (SP-A) levels increased in silica-exposed workers. Surfactant Protein A (SP-A) may be a helpful biomarker for the early diagnosis of pneumoconiosis, but it has not yet been studied in Indonesia.Methods: The design of this study was observational with cross-sectional. A sampling of cement-exposed workers was done by consecutive sampling. The subjects were 88, approach population of 67 cement exposed workers from September 2017 – March 2018 and 17 healthy people as control. The serum level of SP-A was measured by the ELISA method. Cement exposed workers is a worker in the production area and workers in the quarry area.Results: The total number of research subjects met the criteria was 67, and the control subjects were 21. The mean serum SP-A level in the study subject group or the exposed group was 6.02 ng/ml, and the mean SP-A level in the control group was 4.50 ng/ml. The difference in SP-A levels between the exposed and control groups was different but not significant, with value of P=0.084.Conclusion: SP-A levels in the exposed and control groups were different but not statistically significant.
Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M Nur Zam Zam; Harun Iskandar; Nur Ahmad Tabri; Arif Santoso; Nurjannah Lihawa; Harry Akza Putrawan; Ferry Sandra
The Indonesian Biomedical Journal Vol 15, No 5 (2023)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v15i5.2431

Abstract

BACKGROUND: Emergence of drug resistance due to epidermal growth factor receptor (EGFR) Exon 20 T790M poses a challenge in the effective management of non-small cell lung carcinoma (NSCLC). Significant breakthrough in the management of NSCLC with a specific genetic alteration causes substantial condition improvement in patients whose cancer progressed after first-generation tyrosine kinase inhibitor treatment and who developed tumors with EGFR Exon 20 T790M mutation. The present study analyzed a cohort of NSCLC patients and investigated the incidence of the EGFR Exon 20 T790M status with Osimertinib therapy, along with its impact on survival rates.METHODS: This was a retrospective cohort study on 22 NSCLC subjects who were genetically examined for EGFR status from plasmic cell free total nucleic acid. Subjects with EGFR Exon 20 T790M mutation were treated with/without Osimertinib. Demographic and clinical data were descriptively summarized, and the differences of each variable and correlation between survival rate and EGFR Exon 20 T790M were analyzed.RESULTS: Subjects with (n=13) and without (n=9) EGFR Exon 20 T790M had survival rates of 10.77±2.45 and 4.78±1.48, respectively (p=0.000). Based on 1-year survival status of subjects with EGFR Exon 20 T790M, there were 3 Osimertinib-treated survivors and 2 Osimertinib-treated non-survivors. Eight subjects with EGFR Exon 20 T790M and without Osimertinib treatment did not survive (p=0.001).CONCLUSION: Since the treatment of Osimertinib demonstrated a noteworthy survival rate among NSCLC subjects with EGFR Exon 20 T790M, thus Osimertinib could be suggested as a potential targeted therapy for NSCLC subjects with EGFR Exon 20 T790M.KEYWORDS: non-small cell lung carcinoma, EGFR, Exon 20, T790M, osimertinib 
Association Between PAI-1 4G/5G Genetic Polymorphism and Uncontrolled Allergic Asthma Harun Iskandar; Muh Ilyas; Eliana Muis; Nur Ahmad Tabri; Dewi Setiawati
Advance Sustainable Science Engineering and Technology Vol. 7 No. 3 (2025): May - July
Publisher : Science and Technology Research Centre Universitas PGRI Semarang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26877/asset.v7i3.1872

Abstract

Airway remodeling is a major challenge in the management of uncontrolled allergic asthma, despite standard therapy with a combination of inhaled corticosteroids (ICS) and long-acting bronchodilators (LABA). Increased levels of Plasminogen Activator Inhibitor-1 (PAI-1) are thought to play a role in this process, and the 4G/5G polymorphism in the PAI-1 gene is one of the genetic factors that affect it. This study aimed to analyze the association between the 4G/5G PAI-1 genetic polymorphism and uncontrolled allergic asthma. A case-control study was conducted at Wahidin Sudirohusodo General Hospital between January-March 2024 on 40 patients with allergic asthma and 40 non-asthmatic subjects. Diagnosis was made through prik test (+), bronchodilator test (+), and asthma control classification according to GINA criteria. All asthmatic patients received Budesonide-Formoterol therapy for 4 weeks. PAI-1 levels were measured and 4G/5G polymorphism was analyzed by RT-PCR. Results showed that PAI-1 levels were significantly higher in uncontrolled asthma patients and in individuals with the 4G/4G genotype compared to non-4G/4G (2.38 ± 0.770 vs 1.65 ± 0.714; p=0.001). The 4G/4G genotype was more common in uncontrolled asthma (OR: 5.8) and was associated with the risk of severe obstruction (OR: 11.6). Thus, it was concluded that the 4G/4G genotype in the PAI-1 gene is associated with increased PAI-1 levels, risk of uncontrolled allergic asthma, and more severe degree of airway obstruction. The implication of the results shows that genetic testing of PAI-1 has the potential to be a predictive biomarker in personalized asthma therapy strategies. This approach can help clinicians identify high-risk patients and tailor interventions early and effectively to prevent remodeling and reduce long-term morbidity.
Co-Authors Ahmad Hudoyo Arif Santoso Arif Santoso Arif Santoso Arif Santoso Dewi Setiawati Edward Pandu Wiriyansyah Eliana Muis Ferry Sandra Gunawan Gunawan Harry Akza Putrawan Hasan Nyambe Irawaty Djaharuddin Irawaty Djaharudin Muh Ilyas Muh Ilyas Muhammad Ilyas Muhammad Ilyas Nur Ahmad Tabri Nur Ahmad Tabri Nur Ahmad Tabri Nur Ahmad Tabri Nur Zam Zam Nurjannah Lihawa Sita Laksmi Andarini Yacob Arawamin Batkunde